Candesartan Antihypertensive Survival Evaluation in Japan (CASE-J) Trial of Cardiovascular Events in High-Risk Hypertensive Patients: Rationale, Design, and Methods

Tsuguya Fukui(St. Luke's International Hospital), Takao Saruta(Keio University), Tosiya Sato(Ogikubo Hospital), Junichi Sakamoto(Tokai Central Hospital), Toshio Ogihara(Osaka University), Satoshi Morita(Kyoto University), Mahbubur Rahman(Kyoto University), Kazuo Takeda(Kyoto Prefectural University of Medicine), Jitsuo Higaki(Saiseikai Matsuyama Hospital), Masatoshi Fujishima(Kyushu University), Kôichi Hayashi, K Fukiyama(Osaka Ekisaikai Hospital), Masanori Fukushima(Nagoya Institute of Technology)
Hypertension Research
January 1, 2003
10.1291/hypres.26.979
Cited by 53

Related Papers

Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
|New England Journal of Medicine|2010|5.6k
Erratum: The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2009)
|Hypertension Research|2014|1.4k
Pharmacological blood pressure lowering for primary and secondary prevention of cardiovascular disease across different levels of blood pressure: an individual participant-level data meta-analysis
|The Lancet|2021|997
Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an open-label, randomised, multicentre, phase 3 trial
|The Lancet Oncology|2019|642
In vivo transfection of cis element “decoy” against nuclear factor- κB binding site prevents myocardial infarction
|Nature Medicine|1997|589